Skip to main content
main-content
Erschienen in: Die Chirurgie 1/2022

28.10.2021 | GIST | Leitthema

Chirurgische und interdisziplinäre Therapie gastrointestinaler Stromatumoren

verfasst von: Univ.-Prof. Dr. Dr. med. Thomas Schmidt, Markus Ghadimi, Hans F. Fuchs, Christiane J. Bruns

Erschienen in: Die Chirurgie | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Gastrointestinale Stromatumoren (GISTs) sind die häufigsten potenziell malignen mesenchymalen Tumoren des Gastrointestinaltraktes. Seit der Einführung von Imatinib und weiterer Tyrosinkinaseinhibitoren wurde die Therapie von GISTs durch die Inhibition der Tyrosinkinasen c‑Kit und PDGFRα revolutioniert. Trotz der zielgerichteten Therapie ist eine Heilung weiterhin nur durch eine Operation mit Resektion des Primärtumors zu erreichen. Durch eine multimodale interdisziplinäre Therapie kann heute auch in der metastasierten Situation mit kompletter Resektion des Primärtumors und der Metastasen die Prognose erheblich verbessert oder sogar eine Heilung erzielt werden. Eine neoadjuvante Therapie kann das Resektionsausmaß vermindern und hierdurch den Organ(teil)erhalt und eine Verringerung der chirurgischen Morbidität ermöglichen. Um die molekularen und klinischen Prädiktoren regelrecht zu gewichten und die optimale Therapie zu gewährleisten, sollten Patienten mit GISTs, sicher aber Patienten mit fortgeschrittenen GISTs, in interdisziplinären Sarkomboards vorgestellt und beraten werden.
Literatur
1.
Zurück zum Zitat Sircar K et al (1999) Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23(4):377–389 PubMed Sircar K et al (1999) Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23(4):377–389 PubMed
2.
Zurück zum Zitat Emile JF et al (2012) Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 29(3):1765–1772 PubMed Emile JF et al (2012) Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 29(3):1765–1772 PubMed
3.
Zurück zum Zitat Cavnar MJ et al (2021) Outcome of 1000 patients with gastrointestinal stromal tumor (GIST) treated by surgery in the pre- and post-imatinib eras. Ann Surg 273(1):128–138 PubMed Cavnar MJ et al (2021) Outcome of 1000 patients with gastrointestinal stromal tumor (GIST) treated by surgery in the pre- and post-imatinib eras. Ann Surg 273(1):128–138 PubMed
4.
Zurück zum Zitat Nishida T et al (2021) Recent progress and challenges in the diagnosis and treatment of gastrointestinal stromal tumors. Cancers (Basel) 13(13):3158 Nishida T et al (2021) Recent progress and challenges in the diagnosis and treatment of gastrointestinal stromal tumors. Cancers (Basel) 13(13):3158
5.
Zurück zum Zitat von Mehren M, Joensuu H (2018) Gastrointestinal stromal tumors. J Clin Oncol 36(2):136–143 von Mehren M, Joensuu H (2018) Gastrointestinal stromal tumors. J Clin Oncol 36(2):136–143
7.
Zurück zum Zitat Joensuu H et al (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13(3):265–274 PubMed Joensuu H et al (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13(3):265–274 PubMed
8.
Zurück zum Zitat Blanke CD et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625 PubMed Blanke CD et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625 PubMed
9.
Zurück zum Zitat Solaini L et al (2021) Open versus laparoscopic versus robotic gastric gastrointestinal stromal tumour resections: a multicentre cohort study. Int J Med Robot 17(2):e2198 PubMed Solaini L et al (2021) Open versus laparoscopic versus robotic gastric gastrointestinal stromal tumour resections: a multicentre cohort study. Int J Med Robot 17(2):e2198 PubMed
10.
Zurück zum Zitat Chi JL et al (2017) Laparoscopic versus open resection for gastric gastrointestinal stromal tumors (GISTs): a size-location-matched case-control study. World J Surg 41(9):2345–2352 PubMed Chi JL et al (2017) Laparoscopic versus open resection for gastric gastrointestinal stromal tumors (GISTs): a size-location-matched case-control study. World J Surg 41(9):2345–2352 PubMed
12.
Zurück zum Zitat Casali PG et al (2018) Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(4):iv68–iv78 PubMed Casali PG et al (2018) Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(4):iv68–iv78 PubMed
13.
Zurück zum Zitat Demetri GD et al (2007) NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(2):S1–29 (quiz S30) PubMed Demetri GD et al (2007) NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(2):S1–29 (quiz S30) PubMed
14.
Zurück zum Zitat Sepe PS, Brugge WR (2009) A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 6(6):363–371 PubMed Sepe PS, Brugge WR (2009) A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 6(6):363–371 PubMed
15.
Zurück zum Zitat Holmebakk T et al (2018) Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol 25(5):1133–1139 PubMed Holmebakk T et al (2018) Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol 25(5):1133–1139 PubMed
16.
Zurück zum Zitat Holmebakk T et al (2019) Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour. Br J Surg 106(4):419–426 PubMed Holmebakk T et al (2019) Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour. Br J Surg 106(4):419–426 PubMed
17.
Zurück zum Zitat Eriksson M et al (2016) Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour—does it increase the risk for tumour cell seeding and recurrence? Eur J Cancer 59:128–133 PubMed Eriksson M et al (2016) Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour—does it increase the risk for tumour cell seeding and recurrence? Eur J Cancer 59:128–133 PubMed
18.
Zurück zum Zitat Boikos SA et al (2016) Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol 2(7):922–928 PubMedPubMedCentral Boikos SA et al (2016) Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol 2(7):922–928 PubMedPubMedCentral
19.
Zurück zum Zitat Landi B et al (2019) Gastrointestinal stromal tumours (GISTs): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 51(9):1223–1231 PubMed Landi B et al (2019) Gastrointestinal stromal tumours (GISTs): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 51(9):1223–1231 PubMed
20.
Zurück zum Zitat Fiore M et al (2009) Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 35(7):739–745 PubMed Fiore M et al (2009) Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 35(7):739–745 PubMed
21.
Zurück zum Zitat Eisenberg BL et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99(1):42–47 PubMedPubMedCentral Eisenberg BL et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99(1):42–47 PubMedPubMedCentral
22.
Zurück zum Zitat Benjamin RS et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760–1764 PubMed Benjamin RS et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760–1764 PubMed
23.
Zurück zum Zitat Wang D et al (2012) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann Surg Oncol 19(4):1074–1080 PubMed Wang D et al (2012) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann Surg Oncol 19(4):1074–1080 PubMed
24.
Zurück zum Zitat Rutkowski P et al (2013) Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 20(9):2937–2943 PubMed Rutkowski P et al (2013) Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 20(9):2937–2943 PubMed
25.
Zurück zum Zitat Cavnar MJ et al (2017) Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: organ preservation and improved oncologic outcome. Ann Surg Oncol 24(13):3972–3980 PubMedPubMedCentral Cavnar MJ et al (2017) Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: organ preservation and improved oncologic outcome. Ann Surg Oncol 24(13):3972–3980 PubMedPubMedCentral
27.
Zurück zum Zitat Hawkins AT et al (2017) Preoperative chemotherapy and survival for large anorectal gastrointestinal stromal tumors: a national analysis of 333 cases. Ann Surg Oncol 24(5):1195–1201 PubMed Hawkins AT et al (2017) Preoperative chemotherapy and survival for large anorectal gastrointestinal stromal tumors: a national analysis of 333 cases. Ann Surg Oncol 24(5):1195–1201 PubMed
29.
Zurück zum Zitat Kurokawa Y et al (2017) Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117(1):25–32 PubMedPubMedCentral Kurokawa Y et al (2017) Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 117(1):25–32 PubMedPubMedCentral
30.
Zurück zum Zitat Marqueen KE et al (2021) Neoadjuvant therapy for gastrointestinal stromal tumors: a propensity score-weighted analysis. Int J Cancer 149(1):177–185 PubMed Marqueen KE et al (2021) Neoadjuvant therapy for gastrointestinal stromal tumors: a propensity score-weighted analysis. Int J Cancer 149(1):177–185 PubMed
32.
Zurück zum Zitat Hamacher R et al (2019) Imatinib and beyond-what is important for surgery? Chirurg 90(6):462–469 PubMed Hamacher R et al (2019) Imatinib and beyond-what is important for surgery? Chirurg 90(6):462–469 PubMed
33.
Zurück zum Zitat Cavnar MJ et al (2021) Prognostic factors after neoadjuvant Imatinib for newly diagnosed primary gastrointestinal stromal tumor. J Gastrointest Surg 25(7):1828–1836 PubMed Cavnar MJ et al (2021) Prognostic factors after neoadjuvant Imatinib for newly diagnosed primary gastrointestinal stromal tumor. J Gastrointest Surg 25(7):1828–1836 PubMed
34.
Zurück zum Zitat Blesius A et al (2011) Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 11:72 PubMedPubMedCentral Blesius A et al (2011) Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 11:72 PubMedPubMedCentral
35.
Zurück zum Zitat Rutkowski P et al (2007) Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 14(7):2018–2027 PubMed Rutkowski P et al (2007) Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 14(7):2018–2027 PubMed
36.
Zurück zum Zitat DeMatteo RP et al (2013) Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 258(3):422–429 PubMed DeMatteo RP et al (2013) Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 258(3):422–429 PubMed
37.
Zurück zum Zitat Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104 PubMedPubMedCentral Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104 PubMedPubMedCentral
38.
Zurück zum Zitat Corless CL et al (2014) Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 32(15):1563–1570 PubMedPubMedCentral Corless CL et al (2014) Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 32(15):1563–1570 PubMedPubMedCentral
39.
Zurück zum Zitat Casali PG et al (2015) Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with Imatinib as an adjuvant: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the Australasian gastro-intestinal trials group, UNICANCER, French sarcoma group, Italian sarcoma group, and Spanish group for research on sarcomas. J Clin Oncol 33(36):4276–4283 PubMed Casali PG et al (2015) Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with Imatinib as an adjuvant: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the Australasian gastro-intestinal trials group, UNICANCER, French sarcoma group, Italian sarcoma group, and Spanish group for research on sarcomas. J Clin Oncol 33(36):4276–4283 PubMed
40.
Zurück zum Zitat Casali PG et al (2021) Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC soft tissue and Bone sarcoma group (STBSG), the Australasian Gastro-intestinal trials group (AGITG), UNICANCER, French sarcoma group (FSG), Italian sarcoma group (ISG), and Spanish group for research on sarcomas (GEIS)(). Ann Oncol 32(4):533–541 PubMed Casali PG et al (2021) Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC soft tissue and Bone sarcoma group (STBSG), the Australasian Gastro-intestinal trials group (AGITG), UNICANCER, French sarcoma group (FSG), Italian sarcoma group (ISG), and Spanish group for research on sarcomas (GEIS)(). Ann Oncol 32(4):533–541 PubMed
41.
Zurück zum Zitat Joensuu H et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265–1272 PubMed Joensuu H et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265–1272 PubMed
42.
Zurück zum Zitat Joensuu H et al (2016) Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol 34(3):244–250 PubMed Joensuu H et al (2016) Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol 34(3):244–250 PubMed
43.
Zurück zum Zitat Raut CP et al (2018) Efficacy and tolerability of 5‑year adjuvant Imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST‑5 clinical trial. JAMA Oncol 4(12):e184060 PubMedPubMedCentral Raut CP et al (2018) Efficacy and tolerability of 5‑year adjuvant Imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST‑5 clinical trial. JAMA Oncol 4(12):e184060 PubMedPubMedCentral
44.
Zurück zum Zitat Joensuu H et al (2014) Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients. Radiology 271(1):96–103 PubMed Joensuu H et al (2014) Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients. Radiology 271(1):96–103 PubMed
45.
Zurück zum Zitat Verweij J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134 PubMed Verweij J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134 PubMed
46.
Zurück zum Zitat Demetri GD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480 PubMed Demetri GD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480 PubMed
47.
Zurück zum Zitat Casali PG et al (2017) Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels. J Clin Oncol 35(15):1713–1720 PubMed Casali PG et al (2017) Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels. J Clin Oncol 35(15):1713–1720 PubMed
48.
Zurück zum Zitat Blanke CD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632 PubMed Blanke CD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632 PubMed
49.
Zurück zum Zitat Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28(7):1247–1253 Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28(7):1247–1253
50.
Zurück zum Zitat Patel S, Zalcberg JR (2008) Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 44(4):501–509 PubMed Patel S, Zalcberg JR (2008) Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 44(4):501–509 PubMed
51.
Zurück zum Zitat Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338 PubMed Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338 PubMed
52.
Zurück zum Zitat Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302 PubMed Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302 PubMed
53.
Zurück zum Zitat Janku F et al (2020) Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib. J Clin Oncol 38(28):3294–3303 PubMedPubMedCentral Janku F et al (2020) Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib. J Clin Oncol 38(28):3294–3303 PubMedPubMedCentral
55.
Zurück zum Zitat Blay JY et al (2020) Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21(7):923–934 PubMedPubMedCentral Blay JY et al (2020) Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21(7):923–934 PubMedPubMedCentral
56.
Zurück zum Zitat Heinrich MC et al (2020) Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 21(7):935–946 PubMed Heinrich MC et al (2020) Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 21(7):935–946 PubMed
57.
Zurück zum Zitat Bauer S et al (2014) Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib—analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 40(4):412–419 PubMed Bauer S et al (2014) Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib—analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 40(4):412–419 PubMed
58.
Zurück zum Zitat Du CY et al (2014) Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer 50(10):1772–1778 PubMed Du CY et al (2014) Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer 50(10):1772–1778 PubMed
59.
Zurück zum Zitat Xia L et al (2010) Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today 40(10):936–942 PubMed Xia L et al (2010) Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today 40(10):936–942 PubMed
60.
Zurück zum Zitat Raut CP et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24(15):2325–2331 PubMed Raut CP et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24(15):2325–2331 PubMed
61.
Zurück zum Zitat Wada N et al (2021) Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors. Surg Today 51(9):1506–1512 PubMed Wada N et al (2021) Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors. Surg Today 51(9):1506–1512 PubMed
62.
Zurück zum Zitat Yamanaka T et al (2013) Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol 24(3):341–346 PubMed Yamanaka T et al (2013) Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol 24(3):341–346 PubMed
Metadaten
Titel
Chirurgische und interdisziplinäre Therapie gastrointestinaler Stromatumoren
verfasst von
Univ.-Prof. Dr. Dr. med. Thomas Schmidt
Markus Ghadimi
Hans F. Fuchs
Christiane J. Bruns
Publikationsdatum
28.10.2021
Verlag
Springer Medizin
Schlagwörter
GIST
Metastasen
Erschienen in
Die Chirurgie / Ausgabe 1/2022
Print ISSN: 2731-6971
Elektronische ISSN: 2731-698X
DOI
https://doi.org/10.1007/s00104-021-01527-1

Weitere Artikel der Ausgabe 1/2022

Die Chirurgie 1/2022 Zur Ausgabe

Anzeige: Webinare zu Leitlinien in der Chirurgie

S1-Leitlinie „Post-COVID/Long-COVID“

Neu im Fachgebiet Chirurgie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Der einfache Weg sich fortzubilden: Befundungskurs Radiologie

Strukturiertes Interpretieren und Analysieren von radiologischen Befunden